Zoetis (NYSE:ZTS) Lowered to Strong Sell Rating by Zacks Research

Zoetis (NYSE:ZTS) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other brokerages also recently issued reports on ZTS. Citigroup cut their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. William Blair restated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Stifel Nicolaus decreased their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. Finally, Barclays lowered their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $109.62.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $75.23 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The stock has a market capitalization of $31.54 billion, a PE ratio of 12.39, a price-to-earnings-growth ratio of 1.29 and a beta of 0.73. The firm’s 50 day moving average price is $76.57 and its 200-day moving average price is $99.89. Zoetis has a twelve month low of $71.45 and a twelve month high of $160.48.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the business posted $1.76 earnings per share. The firm’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts expect that Zoetis will post 6.19 EPS for the current year.

Institutional Investors Weigh In On Zoetis

Institutional investors and hedge funds have recently bought and sold shares of the business. Louisiana State Employees Retirement System purchased a new position in Zoetis in the 1st quarter worth approximately $2,542,000. Deutsche Bank AG boosted its stake in Zoetis by 19.1% in the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after purchasing an additional 891,921 shares during the period. Pincus Capital Management LP purchased a new stake in Zoetis during the 4th quarter valued at approximately $2,109,000. Highbridge Capital Management LLC purchased a new stake in Zoetis during the 4th quarter valued at approximately $7,004,000. Finally, Pacer Advisors Inc. raised its position in shares of Zoetis by 16.7% during the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after buying an additional 23,687 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Citigroup lowered its Zoetis price target from $112 to $96 but retained a Buy rating, implying substantial upside from recent levels. The continued Buy recommendation may provide support despite the more cautious valuation. Benzinga article
• Positive Sentiment: BNP Paribas Exane cut its target from $146 to $110 while maintaining an Outperform rating. The target still indicates significant potential appreciation, suggesting the firm views recent weakness as excessive relative to Zoetis’ long-term prospects. Tickerreport.com article
• Neutral Sentiment: JPMorgan reduced its Zoetis price target to $115, adding to the pattern of analysts recalibrating estimates without necessarily abandoning the investment case. JPMorgan price target article
• Neutral Sentiment: Piper Sandler lowered its target from $90 to $80 and assigned a Neutral rating. The target remains modestly above the recent share price, but the stance signals limited near-term conviction. Benzinga article
• Negative Sentiment: Recent coverage highlights leadership changes, competitive pressures and concerns surrounding Zoetis’ outlook. The company’s latest quarter also showed revenue down 0.2% year over year, while full-year 2026 EPS guidance of $6.15–$6.25 is below some analyst expectations, weighing on sentiment. ZTS Q2 Deep Dive article

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.